{"protocolSection": {"identificationModule": {"nctId": "NCT02555683", "orgStudyIdInfo": {"id": "CQAW039A2307"}, "secondaryIdInfos": [{"id": "2015-002553-35", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.", "officialTitle": "A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Existing Asthma Therapy in Patients With Uncontrolled Severe Asthma."}, "statusModule": {"statusVerifiedDate": "2020-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-12-11", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2019-10-21", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-11-04", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-09-18", "studyFirstSubmitQcDate": "2015-09-18", "studyFirstPostDateStruct": {"date": "2015-09-21", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2020-05-04", "resultsFirstSubmitQcDate": "2020-05-04", "resultsFirstPostDateStruct": {"date": "2020-05-18", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2020-05-04", "lastUpdatePostDateStruct": {"date": "2020-05-18", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This study aimed to determine the efficacy and safety of QAW039 150 mg and QAW039 450 mg, compared with placebo, when added to GINA (Global Initiative for Asthma) steps 4 and 5 standard-of- care (SoC) asthma therapy (GINA 2016) in the following two populations:\n\n* patient with inadequately controlled severe asthma and high eosinophil counts at baseline (eosinophil count at Visit 1 \u2265250 cells/ \u00b5l) (sub-population)\n* patients with inadequately controlled severe asthma (overall study population)\n\nInadequate control is defined as partly controlled or uncontrolled asthma (GINA 2016).", "detailedDescription": "This study used a randomized, multicenter, double-blind, placebo-controlled parallel-group design in which QAW039 150 mg or QA039 450 mg or placebo was added to standard of care, GINA steps 4 and 5 asthma therapy.\n\nThe study included:\n\n* Screening period of up to 2 weeks to assess eligibility;\n* Run-in period of approximately 2 weeks and a maximum of 6 weeks on placebo to collect baseline data for efficacy variables and compliance with the Electronic Peak Flow/ eDiary device. Upon completion of the run-in period, all patients who met the eligibility criteria were randomized to one of three treatments: QAW039 150 mg or QAW039 450 mg or placebo once daily in a ratio of 1:1:1.\n* Treatment period of 52 weeks (assessment period for all Primary and Secondary Outcome Measures). Clinic visits were scheduled approximately 4 weeks after randomization and then at approximately 8-week intervals during the active-treatment period. Phone calls occurred at specified time points between visits occurring at 8-week intervals. Patients who had successfully completed 52 weeks of treatment in this study were offered an optional participation in a safety study (CQAW039A2315).\n* Follow-up period of 4 weeks, investigational and drug-free, following the last dose of study drug. A follow-up visit occurred approximately 4 weeks (i.e., approximately 30 days) following the last dose of study therapy to complete safety assessments and pregnancy testing (if applicable). the follow-up period applied to all patients except those patients who had entered the safety study (CQAW039A2315) directly after the Week 52 study visit."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "QAW039", "allergic asthma", "allergy triggered asthma", "reactive asthma", "asthma attack", "difficulty breathing"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 894, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "QAW039 150 mg", "type": "EXPERIMENTAL", "description": "QAW039 150 mg once daily", "interventionNames": ["Drug: QAW039"]}, {"label": "QAW039 450 mg", "type": "EXPERIMENTAL", "description": "QAW039 450 mg once daily", "interventionNames": ["Drug: QAW039"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo once daily", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "QAW039", "description": "QAW039 150 mg once daily", "armGroupLabels": ["QAW039 150 mg"]}, {"type": "DRUG", "name": "QAW039", "description": "QAW039 450 mg once daily", "armGroupLabels": ["QAW039 450 mg"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo once daily", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation", "description": "A severe asthma exacerbation is defined as treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days and hospitalization; or treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days and emergency department visit (greater than 24 hours\\*); or death due to asthma. A moderate asthma exacerbation is defined as treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days either as an outpatient or in emergency department visits (Emergency department visit less than or equal to 24 hours). The high eosinophils subpopulation consists of all patients with blood eosinophil count \u2265 250 cells/\u03bcL at baseline.", "timeFrame": "Baseline, Week 52"}, {"measure": "Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in Overall Population", "description": "A severe asthma exacerbation is defined as treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days and hospitalization; or treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days and emergency department visit (greater than 24 hours\\*); or death due to asthma. A moderate asthma exacerbation is defined as treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days either as an outpatient or in emergency department visits (Emergency department visit less than or equal to 24 hours).", "timeFrame": "Baseline, Week 52"}], "secondaryOutcomes": [{"measure": "Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for Participants 12 Years and Older (AQLQ+12) Score in High Eosinophils Subpopulation", "description": "The AQLQ+12 is comprised of a total of 32 individual questions that span a total of four domains: symptoms, activity limitation, emotional function, and environmental stimuli.\n\nPatients were asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale (7 = not at all impaired to 1 = severely impaired). The AQLQ+12 yields individual domain scores, which is the mean of all items in each domain, and an overall score, which is the mean of all 32 individual responses. Higher scores indicate less impairment in health-related quality of life. The high eosinophils subpopulation consists of all patients with blood eosinophil count \u2265 250 cells/\u03bcL at baseline.", "timeFrame": "52 weeks"}, {"measure": "Change From Baseline to Week 52 in Asthma Control Questionnaire-5(ACQ-5) Score in High Eosinophils Subpopulation", "description": "The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma control of a participant. Patients were asked to recall how their asthma had been during the previous week and to respond to the symptom questions on a 7-point scale (0=no impairment, 6=maximum impairment). The questions are equally weighted and the ACQ-5 score is the mean of the 5 questions: therefore, between 0 (totally controlled) and 6 (severely uncontrolled). The high eosinophils subpopulation consists of all patients with blood eosinophil count \u2265 250 cells/\u03bcL at baseline.", "timeFrame": "Baseline, Week 52"}, {"measure": "Change From Baseline to Week 52 in Pre-dose Forced Expiratory Volume in 1 Second (FEV1) in High Eosinophils Subpopulation", "description": "Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Baseline is defined as the last available FEV1 measurement taken prior to the first dose of randomized study drug. The high eosinophils subpopulation consists of all patients with blood eosinophil count \u2265 250 cells/\u03bcL at baseline.", "timeFrame": "Baseline, Week 52"}, {"measure": "Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for Participants 12 Years and Older (AQLQ+12) Score in Overall Population", "description": "The AQLQ+12 is comprised of a total of 32 individual questions that span a total of four domains: symptoms, activity limitation, emotional function, and environmental stimuli.\n\nPatients were asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale (7 = not at all impaired to 1 = severely impaired). The AQLQ+12 yields individual domain scores, which is the mean of all items in each domain, and an overall score, which is the mean of all 32 individual responses. Higher scores indicate less impairment in health-related quality of life.", "timeFrame": "Baseline, Week 52"}, {"measure": "Change From Baseline to Week 52 in Asthma Control Questionnaire-5(ACQ-5) Score in Overall Population", "description": "The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma control of a participant. Patients were asked to recall how their asthma had been during the previous week and to respond to the symptom questions on a 7-point scale (0=no impairment, 6=maximum impairment). The questions are equally weighted and the ACQ-5 score is the mean of the 5 questions: therefore, between 0 (totally controlled) and 6 (severely uncontrolled).", "timeFrame": "Baseline, Week 52"}, {"measure": "Change From Baseline to Week 52 in Pre-dose Forced Expiratory Volume in 1 Second (FEV1) in Overall Population", "description": "Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Baseline is defined as the last available FEV1 measurement taken prior to the first dose of randomized study drug.", "timeFrame": "Baseline, Week 52"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Written informed consent and assent (if applicable).\n* Male and female patients aged \u226512 years (or \u2265lower age limit allowed by health authority and/or ethics committee/institutional review board approvals).\n* A diagnosis of severe asthma, uncontrolled on GINA 4/5 asthma medication.\n* Evidence of airway reversibility or airway hyper- reactivity.\n* FEV1 of \u226480% of the predicted normal value for patients aged \u226518 years; FEV1 of \u226490% for patients aged 12 to \\<18 years\n* An ACQ score \u22651.5.\n* A history of 2 or more asthma exacerbations within the 12 months prior to entering the study.\n\nExclusion Criteria:\n\n* Use of other investigational drugs within 5 half-lives of study entry, or within 30 days, whichever is longer.\n* Subjects who have participated in another trial of QAW039.\n* A QTcF (Fridericia) \u2265450 msec (male) or \u2265460 msec (female).\n* History of malignancy with the exception of local basal cell carcinoma of the skin.\n* Pregnant or nursing (lactating) women.\n* Serious co-morbidities.\n* Patients on greater than 20 mg of simvastatin, greater than 40 mg of atorvastatin, greater than 40 mg of pravastatin, or greater than 2 mg of pitavastatin", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "12 Years", "stdAges": ["CHILD", "ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novartis Investigative Site", "city": "Birmingham", "state": "Alabama", "zip": "35209", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Novartis Investigative Site", "city": "Birmingham", "state": "Alabama", "zip": "35249", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Novartis Investigative Site", "city": "Gilbert", "state": "Arizona", "zip": "85234", "country": "United States", "geoPoint": {"lat": 33.35283, "lon": -111.78903}}, {"facility": "Novartis Investigative Site", "city": "Litchfield Park", "state": "Arizona", "zip": "85340", "country": "United States", "geoPoint": {"lat": 33.49337, "lon": -112.35794}}, {"facility": "Novartis Investigative Site", "city": "Peoria", "state": "Arizona", "zip": "85381", "country": "United States", "geoPoint": {"lat": 33.5806, "lon": -112.23738}}, {"facility": "Novartis Investigative Site", "city": "Little Rock", "state": "Arkansas", "zip": "72209", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Novartis Investigative Site", "city": "Hawaiian Gardens", "state": "California", "zip": "90716", "country": "United States", "geoPoint": {"lat": 33.8314, "lon": -118.07284}}, {"facility": "Novartis Investigative Site", "city": "Newport Beach", "state": "California", "zip": "92663", "country": "United States", "geoPoint": {"lat": 33.61891, "lon": -117.92895}}, {"facility": "Novartis Investigative Site", "city": "Redondo Beach", "state": "California", "zip": "90277", "country": "United States", "geoPoint": {"lat": 33.84918, "lon": -118.38841}}, {"facility": "Novartis Investigative Site", "city": "Riverside", "state": "California", "zip": "92506", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "Novartis Investigative Site", "city": "Torrance", "state": "California", "zip": "90503", "country": "United States", "geoPoint": {"lat": 33.83585, "lon": -118.34063}}, {"facility": "Novartis Investigative Site", "city": "Westminster", "state": "California", "zip": "92683", "country": "United States", "geoPoint": {"lat": 33.75918, "lon": -118.00673}}, {"facility": "Novartis Investigative Site", "city": "New Haven", "state": "Connecticut", "zip": "06520", "country": "United States", "geoPoint": {"lat": 41.30815, "lon": -72.92816}}, {"facility": "Novartis Investigative Site", "city": "Brandon", "state": "Florida", "zip": "33511", "country": "United States", "geoPoint": {"lat": 27.9378, "lon": -82.28592}}, {"facility": "Novartis Investigative Site", "city": "New Smyrna Beach", "state": "Florida", "zip": "32168", "country": "United States", "geoPoint": {"lat": 29.02582, "lon": -80.927}}, {"facility": "Novartis Investigative Site", "city": "Orlando", "state": "Florida", "zip": "32803", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Novartis Investigative Site", "city": "Orlando", "state": "Florida", "zip": "32806", "country": "United States", "geoPoint": {"lat": 28.53834, "lon": -81.37924}}, {"facility": "Novartis Investigative Site", "city": "Ormond Beach", "state": "Florida", "zip": "32174", "country": "United States", "geoPoint": {"lat": 29.28581, "lon": -81.05589}}, {"facility": "Novartis Investigative Site", "city": "Sebring", "state": "Florida", "zip": "33870", "country": "United States", "geoPoint": {"lat": 27.49559, "lon": -81.44091}}, {"facility": "Novartis Investigative Site", "city": "Winter Park", "state": "Florida", "zip": "32789", "country": "United States", "geoPoint": {"lat": 28.6, "lon": -81.33924}}, {"facility": "Novartis Investigative Site", "city": "Gainesville", "state": "Georgia", "zip": "30501", "country": "United States", "geoPoint": {"lat": 34.29788, "lon": -83.82407}}, {"facility": "Novartis Investigative Site", "city": "Marietta", "state": "Georgia", "zip": "30060", "country": "United States", "geoPoint": {"lat": 33.9526, "lon": -84.54993}}, {"facility": "Novartis Investigative Site", "city": "Crowley", "state": "Louisiana", "zip": "70526", "country": "United States", "geoPoint": {"lat": 30.21409, "lon": -92.37458}}, {"facility": "Novartis Investigative Site", "city": "Zachary", "state": "Louisiana", "zip": "70791", "country": "United States", "geoPoint": {"lat": 30.64852, "lon": -91.1565}}, {"facility": "Novartis Investigative Site", "city": "Bangor", "state": "Maine", "zip": "04401", "country": "United States", "geoPoint": {"lat": 44.80118, "lon": -68.77781}}, {"facility": "Novartis Investigative Site", "city": "Gaithersburg", "state": "Maryland", "zip": "20878", "country": "United States", "geoPoint": {"lat": 39.14344, "lon": -77.20137}}, {"facility": "Novartis Investigative Site", "city": "White Marsh", "state": "Maryland", "zip": "21162", "country": "United States", "geoPoint": {"lat": 39.38372, "lon": -76.43218}}, {"facility": "Novartis Investigative Site", "city": "Livonia", "state": "Michigan", "zip": "48152", "country": "United States", "geoPoint": {"lat": 42.36837, "lon": -83.35271}}, {"facility": "Novartis Investigative Site", "city": "Ypsilanti", "state": "Michigan", "zip": "48197", "country": "United States", "geoPoint": {"lat": 42.24115, "lon": -83.61299}}, {"facility": "Novartis Investigative Site", "city": "Picayune", "state": "Mississippi", "zip": "39466", "country": "United States", "geoPoint": {"lat": 30.52556, "lon": -89.67788}}, {"facility": "Novartis Investigative Site", "city": "Bellevue", "state": "Nebraska", "zip": "68123", "country": "United States", "geoPoint": {"lat": 41.13667, "lon": -95.89084}}, {"facility": "Novartis Investigative Site", "city": "Lincoln", "state": "Nebraska", "zip": "68510", "country": "United States", "geoPoint": {"lat": 40.8, "lon": -96.66696}}, {"facility": "Novartis Investigative Site", "city": "Omaha", "state": "Nebraska", "zip": "68131", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "Novartis Investigative Site", "city": "Corning", "state": "New York", "zip": "14830", "country": "United States", "geoPoint": {"lat": 42.14285, "lon": -77.05469}}, {"facility": "Novartis Investigative Site", "city": "New York", "state": "New York", "zip": "10016", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Novartis Investigative Site", "city": "Charlotte", "state": "North Carolina", "zip": "28277", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Novartis Investigative Site", "city": "Gastonia", "state": "North Carolina", "zip": "28054", "country": "United States", "geoPoint": {"lat": 35.26208, "lon": -81.1873}}, {"facility": "Novartis Investigative Site", "city": "Monroe", "state": "North Carolina", "zip": "28112", "country": "United States", "geoPoint": {"lat": 34.98543, "lon": -80.54951}}, {"facility": "Novartis Investigative Site", "city": "New Bern", "state": "North Carolina", "zip": "28562", "country": "United States", "geoPoint": {"lat": 35.10849, "lon": -77.04411}}, {"facility": "Novartis Investigative Site", "city": "Whiteville", "state": "North Carolina", "zip": "28472", "country": "United States", "geoPoint": {"lat": 34.33878, "lon": -78.70307}}, {"facility": "Novartis Investigative Site", "city": "Wilmington", "state": "North Carolina", "zip": "28401", "country": "United States", "geoPoint": {"lat": 34.22573, "lon": -77.94471}}, {"facility": "Novartis Investigative Site", "city": "Winston-Salem", "state": "North Carolina", "zip": "27103", "country": "United States", "geoPoint": {"lat": 36.09986, "lon": -80.24422}}, {"facility": "Novartis Investigative Site", "city": "Canton", "state": "Ohio", "zip": "44718", "country": "United States", "geoPoint": {"lat": 40.79895, "lon": -81.37845}}, {"facility": "Novartis Investigative Site", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Novartis Investigative Site", "city": "Maumee", "state": "Ohio", "zip": "43537", "country": "United States", "geoPoint": {"lat": 41.56283, "lon": -83.65382}}, {"facility": "Novartis Investigative Site", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73120", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Novartis Investigative Site", "city": "Jefferson Hills", "state": "Pennsylvania", "zip": "15025", "country": "United States", "geoPoint": {"lat": 40.29118, "lon": -79.93199}}, {"facility": "Novartis Investigative Site", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15213", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Novartis Investigative Site", "city": "East Providence", "state": "Rhode Island", "zip": "02941", "country": "United States", "geoPoint": {"lat": 41.81371, "lon": -71.37005}}, {"facility": "Novartis Investigative Site", "city": "Boerne", "state": "Texas", "zip": "78006", "country": "United States", "geoPoint": {"lat": 29.79466, "lon": -98.73197}}, {"facility": "Novartis Investigative Site", "city": "McKinney", "state": "Texas", "zip": "75069", "country": "United States", "geoPoint": {"lat": 33.19762, "lon": -96.61527}}, {"facility": "Novartis Investigative Site", "city": "Plano", "state": "Texas", "zip": "75093", "country": "United States", "geoPoint": {"lat": 33.01984, "lon": -96.69889}}, {"facility": "Novartis Investigative Site", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Novartis Investigative Site", "city": "San Antonio", "state": "Texas", "zip": "78251", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Novartis Investigative Site", "city": "Fairfax", "state": "Virginia", "zip": "22030", "country": "United States", "geoPoint": {"lat": 38.84622, "lon": -77.30637}}, {"facility": "Novartis Investigative Site", "city": "Caba", "state": "Buenos Aires", "zip": "C1425BEN", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Novartis Investigative Site", "city": "San Miguel de Tucuman", "state": "Tucuman", "zip": "4000", "country": "Argentina", "geoPoint": {"lat": -26.82414, "lon": -65.2226}}, {"facility": "Novartis Investigative Site", "city": "Buenos Aires", "zip": "C1012AAR", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Novartis Investigative Site", "city": "Ciudad Autonoma de Bs As", "zip": "C1425FVH", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Novartis Investigative Site", "city": "Bedford Park", "state": "South Australia", "zip": "5041", "country": "Australia", "geoPoint": {"lat": -35.03333, "lon": 138.56667}}, {"facility": "Novartis Investigative Site", "city": "Clayton", "state": "Victoria", "zip": "3168", "country": "Australia", "geoPoint": {"lat": -37.91667, "lon": 145.11667}}, {"facility": "Novartis Investigative Site", "city": "Footscray", "state": "Victoria", "zip": "3011", "country": "Australia", "geoPoint": {"lat": -37.8, "lon": 144.9}}, {"facility": "Novartis Investigative Site", "city": "Heidelberg", "state": "Victoria", "zip": "3084", "country": "Australia", "geoPoint": {"lat": -37.75, "lon": 145.06667}}, {"facility": "Novartis Investigative Site", "city": "Melbourne", "state": "Victoria", "zip": "3004", "country": "Australia", "geoPoint": {"lat": -37.814, "lon": 144.96332}}, {"facility": "Novartis Investigative Site", "city": "Innsbruck", "state": "Tyrol", "zip": "6020", "country": "Austria", "geoPoint": {"lat": 47.26266, "lon": 11.39454}}, {"facility": "Novartis Investigative Site", "city": "Amstetten", "zip": "3300", "country": "Austria", "geoPoint": {"lat": 48.1229, "lon": 14.87206}}, {"facility": "Novartis Investigative Site", "city": "Feldkirch", "zip": "6800", "country": "Austria", "geoPoint": {"lat": 47.23306, "lon": 9.6}}, {"facility": "Novartis Investigative Site", "city": "Graz", "zip": "8036", "country": "Austria", "geoPoint": {"lat": 47.06667, "lon": 15.45}}, {"facility": "Novartis Investigative Site", "city": "Thalheim bei Wels", "zip": "4600", "country": "Austria", "geoPoint": {"lat": 48.15, "lon": 14.03333}}, {"facility": "Novartis Investigative Site", "city": "Vienna", "zip": "A-1130", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"facility": "Novartis Investigative Site", "city": "Wien", "zip": "A 1090", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"facility": "Novartis Investigative Site", "city": "Wien", "zip": "A-1140", "country": "Austria", "geoPoint": {"lat": 48.20849, "lon": 16.37208}}, {"facility": "Novartis Investigative Site", "city": "Genk", "state": "Limburg", "zip": "3600", "country": "Belgium", "geoPoint": {"lat": 50.965, "lon": 5.50082}}, {"facility": "Novartis Investigative Site", "city": "Aalst", "zip": "9300", "country": "Belgium", "geoPoint": {"lat": 50.93604, "lon": 4.0355}}, {"facility": "Novartis Investigative Site", "city": "Brussel", "zip": "1020", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "Novartis Investigative Site", "city": "Bruxelles", "zip": "1000", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "Novartis Investigative Site", "city": "Bruxelles", "zip": "1160", "country": "Belgium", "geoPoint": {"lat": 50.85045, "lon": 4.34878}}, {"facility": "Novartis Investigative Site", "city": "Eghezee", "zip": "5310", "country": "Belgium", "geoPoint": {"lat": 50.59076, "lon": 4.91175}}, {"facility": "Novartis Investigative Site", "city": "Erpent", "zip": "5100", "country": "Belgium", "geoPoint": {"lat": 50.45116, "lon": 4.90557}}, {"facility": "Novartis Investigative Site", "city": "Herentals", "zip": "2200", "country": "Belgium", "geoPoint": {"lat": 51.17655, "lon": 4.83248}}, {"facility": "Novartis Investigative Site", "city": "Kortrijk", "zip": "8500", "country": "Belgium", "geoPoint": {"lat": 50.82803, "lon": 3.26487}}, {"facility": "Novartis Investigative Site", "city": "Liege", "zip": "4000", "country": "Belgium", "geoPoint": {"lat": 50.63373, "lon": 5.56749}}, {"facility": "Novartis Investigative Site", "city": "Ottignies", "zip": "1340", "country": "Belgium", "geoPoint": {"lat": 50.66535, "lon": 4.56679}}, {"facility": "Novartis Investigative Site", "city": "Porto Alegre", "state": "Porto Alegre RS", "zip": "90610 000", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Novartis Investigative Site", "city": "Rio de Janeiro", "state": "RJ", "zip": "21941-590", "country": "Brazil", "geoPoint": {"lat": -22.90278, "lon": -43.2075}}, {"facility": "Novartis Investigative Site", "city": "Porto Alegre", "state": "RS", "zip": "90020-090", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Novartis Investigative Site", "city": "Blumenau", "state": "Santa Catarina", "zip": "89030101", "country": "Brazil", "geoPoint": {"lat": -26.91944, "lon": -49.06611}}, {"facility": "Novartis Investigative Site", "city": "Florianopolis", "state": "SC", "zip": "88040-970", "country": "Brazil", "geoPoint": {"lat": -27.59667, "lon": -48.54917}}, {"facility": "Novartis Investigative Site", "city": "Sao Bernardo do Campo", "state": "SP", "zip": "09715 090", "country": "Brazil", "geoPoint": {"lat": -23.69389, "lon": -46.565}}, {"facility": "Novartis Investigative Site", "city": "Sao Paulo", "state": "SP", "zip": "04023-900", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "Novartis Investigative Site", "city": "Sao Paulo", "state": "SP", "zip": "05403 000", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "Novartis Investigative Site", "city": "Sao Paulo", "state": "SP", "zip": "05437 010", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "Novartis Investigative Site", "city": "Guang Zhou", "state": "Guang Dong Province", "zip": "510120", "country": "China"}, {"facility": "Novartis Investigative Site", "city": "Haikou", "state": "Hainan", "zip": "570311", "country": "China", "geoPoint": {"lat": 20.04583, "lon": 110.34167}}, {"facility": "Novartis Investigative Site", "city": "Shijiazhuang", "state": "Hebei", "zip": "050000", "country": "China", "geoPoint": {"lat": 38.04139, "lon": 114.47861}}, {"facility": "Novartis Investigative Site", "city": "Wuhan", "state": "Hubei", "zip": "430030", "country": "China", "geoPoint": {"lat": 30.58333, "lon": 114.26667}}, {"facility": "Novartis Investigative Site", "city": "Nanjing", "state": "Jiangsu", "zip": "210006", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "Novartis Investigative Site", "city": "Nanjing", "state": "Jiangsu", "zip": "210009", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "Novartis Investigative Site", "city": "Nanchang", "state": "Jiangxi", "zip": "330006", "country": "China", "geoPoint": {"lat": 28.68396, "lon": 115.85306}}, {"facility": "Novartis Investigative Site", "city": "Chang Chun", "state": "Jilin", "zip": "130021", "country": "China", "geoPoint": {"lat": 42.74694, "lon": 126.24667}}, {"facility": "Novartis Investigative Site", "city": "Shenyang", "state": "Liaoning", "zip": "110000", "country": "China", "geoPoint": {"lat": 41.79222, "lon": 123.43278}}, {"facility": "Novartis Investigative Site", "city": "Shenyang", "state": "Liaoning", "zip": "110003", "country": "China", "geoPoint": {"lat": 41.79222, "lon": 123.43278}}, {"facility": "Novartis Investigative Site", "city": "Xian", "state": "Shanxi", "zip": "710061", "country": "China", "geoPoint": {"lat": 34.25833, "lon": 108.92861}}, {"facility": "Novartis Investigative Site", "city": "Chengdu", "state": "Sichuan", "zip": "610041", "country": "China", "geoPoint": {"lat": 30.66667, "lon": 104.06667}}, {"facility": "Novartis Investigative Site", "city": "Hangzhou", "state": "Zhejiang", "zip": "310014", "country": "China", "geoPoint": {"lat": 30.29365, "lon": 120.16142}}, {"facility": "Novartis Investigative Site", "city": "Beijing", "zip": "100050", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Novartis Investigative Site", "city": "Chengdu", "zip": "610083", "country": "China", "geoPoint": {"lat": 30.66667, "lon": 104.06667}}, {"facility": "Novartis Investigative Site", "city": "Chongqing", "zip": "400037", "country": "China", "geoPoint": {"lat": 29.56278, "lon": 106.55278}}, {"facility": "Novartis Investigative Site", "city": "Shanghai", "zip": "200433", "country": "China", "geoPoint": {"lat": 31.22222, "lon": 121.45806}}, {"facility": "Novartis Investigative Site", "city": "Tianjin", "zip": "300052", "country": "China", "geoPoint": {"lat": 39.14222, "lon": 117.17667}}, {"facility": "Novartis Investigative Site", "city": "Copenhagen NV", "zip": "2400", "country": "Denmark", "geoPoint": {"lat": 55.67594, "lon": 12.56553}}, {"facility": "Novartis Investigative Site", "city": "Tallinn", "zip": "13419", "country": "Estonia", "geoPoint": {"lat": 59.43696, "lon": 24.75353}}, {"facility": "Novartis Investigative Site", "city": "Tallinn", "zip": "13619", "country": "Estonia", "geoPoint": {"lat": 59.43696, "lon": 24.75353}}, {"facility": "Novartis Investigative Site", "city": "Tartu", "zip": "51014", "country": "Estonia", "geoPoint": {"lat": 58.38062, "lon": 26.72509}}, {"facility": "Novartis Investigative Site", "city": "Helsinki", "zip": "00290", "country": "Finland", "geoPoint": {"lat": 60.16952, "lon": 24.93545}}, {"facility": "Novartis Investigative Site", "city": "HUS", "zip": "00029", "country": "Finland"}, {"facility": "Novartis Investigative Site", "city": "OYS", "zip": "FIN-90029", "country": "Finland"}, {"facility": "Novartis Investigative Site", "city": "Tampere", "zip": "33520", "country": "Finland", "geoPoint": {"lat": 61.49911, "lon": 23.78712}}, {"facility": "Novartis Investigative Site", "city": "Montpellier cedex 5", "state": "Herault", "zip": "34059", "country": "France", "geoPoint": {"lat": 43.61092, "lon": 3.87723}}, {"facility": "Novartis Investigative Site", "city": "Dijon", "zip": "21000", "country": "France", "geoPoint": {"lat": 47.31667, "lon": 5.01667}}, {"facility": "Novartis Investigative Site", "city": "Le Kremlin Bicetre", "zip": "94275", "country": "France", "geoPoint": {"lat": 48.81471, "lon": 2.36073}}, {"facility": "Novartis Investigative Site", "city": "Lyon Cedex 04", "zip": "69317", "country": "France", "geoPoint": {"lat": 45.74848, "lon": 4.84669}}, {"facility": "Novartis Investigative Site", "city": "Marseille", "zip": "13015", "country": "France", "geoPoint": {"lat": 43.29551, "lon": 5.38958}}, {"facility": "Novartis Investigative Site", "city": "Nantes", "zip": "44093", "country": "France", "geoPoint": {"lat": 47.21725, "lon": -1.55336}}, {"facility": "Novartis Investigative Site", "city": "Paris", "zip": "75018", "country": "France", "geoPoint": {"lat": 48.85341, "lon": 2.3488}}, {"facility": "Novartis Investigative Site", "city": "Reims Cedex", "zip": "51092", "country": "France", "geoPoint": {"lat": 49.25, "lon": 4.03333}}, {"facility": "Novartis Investigative Site", "city": "Strasbourg Cedex", "zip": "67091", "country": "France", "geoPoint": {"lat": 48.58392, "lon": 7.74553}}, {"facility": "Novartis Investigative Site", "city": "Heidelberg", "state": "Baden-W\u00fcrttemberg", "zip": "69126", "country": "Germany", "geoPoint": {"lat": 49.40768, "lon": 8.69079}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "10717", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "10969", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "12159", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "12203", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "12627", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Berlin", "zip": "13187", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novartis Investigative Site", "city": "Frankfurt", "zip": "60313", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Novartis Investigative Site", "city": "Frankfurt", "zip": "60389", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Novartis Investigative Site", "city": "Frankfurt", "zip": "60596", "country": "Germany", "geoPoint": {"lat": 50.11552, "lon": 8.68417}}, {"facility": "Novartis Investigative Site", "city": "Halle", "zip": "06108", "country": "Germany", "geoPoint": {"lat": 51.48159, "lon": 11.97948}}, {"facility": "Novartis Investigative Site", "city": "Hamburg", "zip": "20354", "country": "Germany", "geoPoint": {"lat": 53.57532, "lon": 10.01534}}, {"facility": "Novartis Investigative Site", "city": "Landsberg", "zip": "86899", "country": "Germany", "geoPoint": {"lat": 51.52698, "lon": 12.16076}}, {"facility": "Novartis Investigative Site", "city": "Leipzig", "zip": "04103", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Novartis Investigative Site", "city": "Leipzig", "zip": "04357", "country": "Germany", "geoPoint": {"lat": 51.33962, "lon": 12.37129}}, {"facility": "Novartis Investigative Site", "city": "Magdeburg", "zip": "39120", "country": "Germany", "geoPoint": {"lat": 52.12773, "lon": 11.62916}}, {"facility": "Novartis Investigative Site", "city": "Mainz", "zip": "55131", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "Novartis Investigative Site", "city": "Marburg", "zip": "D-35037", "country": "Germany", "geoPoint": {"lat": 50.80904, "lon": 8.77069}}, {"facility": "Novartis Investigative Site", "city": "Neu Isenburg", "zip": "63263", "country": "Germany", "geoPoint": {"lat": 50.04832, "lon": 8.69406}}, {"facility": "Novartis Investigative Site", "city": "Rosenheim", "zip": "83026", "country": "Germany", "geoPoint": {"lat": 47.85637, "lon": 12.12247}}, {"facility": "Novartis Investigative Site", "city": "Rostock", "zip": "18057", "country": "Germany", "geoPoint": {"lat": 54.0887, "lon": 12.14049}}, {"facility": "Novartis Investigative Site", "city": "Rudersdorf", "zip": "15562", "country": "Germany", "geoPoint": {"lat": 51.1, "lon": 11.45}}, {"facility": "Novartis Investigative Site", "city": "Witten", "zip": "58452", "country": "Germany", "geoPoint": {"lat": 51.44362, "lon": 7.35258}}, {"facility": "Novartis Investigative Site", "city": "Thessaloniki", "state": "GR", "zip": "570 10", "country": "Greece", "geoPoint": {"lat": 40.64361, "lon": 22.93086}}, {"facility": "Novartis Investigative Site", "city": "Ciudad", "state": "Gautemala", "zip": "01010", "country": "Guatemala"}, {"facility": "Novartis Investigative Site", "city": "Guatemala City", "state": "GTM", "zip": "01010", "country": "Guatemala", "geoPoint": {"lat": 14.64072, "lon": -90.51327}}, {"facility": "Novartis Investigative Site", "city": "Guatemala City", "state": "GTM", "zip": "01011", "country": "Guatemala", "geoPoint": {"lat": 14.64072, "lon": -90.51327}}, {"facility": "Novartis Investigative Site", "city": "Guatemala City", "zip": "01010", "country": "Guatemala", "geoPoint": {"lat": 14.64072, "lon": -90.51327}}, {"facility": "Novartis Investigative Site", "city": "Guatemala City", "zip": "01011", "country": "Guatemala", "geoPoint": {"lat": 14.64072, "lon": -90.51327}}, {"facility": "Novartis Investigative Site", "city": "Eger", "state": "HUN", "zip": "3300", "country": "Hungary", "geoPoint": {"lat": 47.90265, "lon": 20.37329}}, {"facility": "Novartis Investigative Site", "city": "Gyor", "state": "HUN", "zip": "9024", "country": "Hungary", "geoPoint": {"lat": 47.68333, "lon": 17.63512}}, {"facility": "Novartis Investigative Site", "city": "Hajdunanas", "state": "HUN", "zip": "4080", "country": "Hungary", "geoPoint": {"lat": 47.85, "lon": 21.43333}}, {"facility": "Novartis Investigative Site", "city": "Mako", "state": "HUN", "zip": "6900", "country": "Hungary", "geoPoint": {"lat": 46.21667, "lon": 20.48333}}, {"facility": "Novartis Investigative Site", "city": "Szazhalombatta", "state": "HUN", "zip": "2440", "country": "Hungary", "geoPoint": {"lat": 47.32579, "lon": 18.92141}}, {"facility": "Novartis Investigative Site", "city": "Torokbalint", "state": "Pest", "zip": "2045", "country": "Hungary", "geoPoint": {"lat": 47.42931, "lon": 18.91356}}, {"facility": "Novartis Investigative Site", "city": "Komarom", "zip": "2900", "country": "Hungary", "geoPoint": {"lat": 47.74318, "lon": 18.11913}}, {"facility": "Novartis Investigative Site", "city": "Pecs", "zip": "7635", "country": "Hungary", "geoPoint": {"lat": 46.08333, "lon": 18.23333}}, {"facility": "Novartis Investigative Site", "city": "Reykjavik", "zip": "109", "country": "Iceland", "geoPoint": {"lat": 64.13548, "lon": -21.89541}}, {"facility": "Novartis Investigative Site", "city": "Dublin", "zip": "24", "country": "Ireland", "geoPoint": {"lat": 53.33306, "lon": -6.24889}}, {"facility": "Novartis Investigative Site", "city": "Dublin", "zip": "DUBLIN 8", "country": "Ireland", "geoPoint": {"lat": 53.33306, "lon": -6.24889}}, {"facility": "Novartis Investigative Site", "city": "Daugavpils", "zip": "LV-5401", "country": "Latvia", "geoPoint": {"lat": 55.88333, "lon": 26.53333}}, {"facility": "Novartis Investigative Site", "city": "Daugavpils", "zip": "LV-5417", "country": "Latvia", "geoPoint": {"lat": 55.88333, "lon": 26.53333}}, {"facility": "Novartis Investigative Site", "city": "Riga", "zip": "LV 1002", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"facility": "Novartis Investigative Site", "city": "Kaunas", "state": "LTU", "zip": "LT 50161", "country": "Lithuania", "geoPoint": {"lat": 54.90272, "lon": 23.90961}}, {"facility": "Novartis Investigative Site", "city": "Klaipeda", "state": "LTU", "zip": "LT-93220", "country": "Lithuania", "geoPoint": {"lat": 55.70888, "lon": 21.14311}}, {"facility": "Novartis Investigative Site", "city": "Vilnius", "state": "LTU", "zip": "LT-05263", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "Novartis Investigative Site", "city": "Vilnius", "state": "LTU", "zip": "LT-08406", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "Novartis Investigative Site", "city": "Vilnius", "state": "LTU", "zip": "LT-10207", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"facility": "Novartis Investigative Site", "city": "Kaunas", "state": "LT", "zip": "LT-50128", "country": "Lithuania", "geoPoint": {"lat": 54.90272, "lon": 23.90961}}, {"facility": "Novartis Investigative Site", "city": "Kaunas", "zip": "LT-45130", "country": "Lithuania", "geoPoint": {"lat": 54.90272, "lon": 23.90961}}, {"facility": "Novartis Investigative Site", "city": "Klaipeda", "zip": "LT-92231", "country": "Lithuania", "geoPoint": {"lat": 55.70888, "lon": 21.14311}}, {"facility": "Novartis Investigative Site", "city": "Bulacan", "zip": "3020", "country": "Philippines", "geoPoint": {"lat": 14.79278, "lon": 120.87889}}, {"facility": "Novartis Investigative Site", "city": "Manila", "zip": "1000", "country": "Philippines", "geoPoint": {"lat": 14.6042, "lon": 120.9822}}, {"facility": "Novartis Investigative Site", "city": "Quezon City", "zip": "1100", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "Novartis Investigative Site", "city": "Kielce", "state": "POL", "zip": "25-371", "country": "Poland", "geoPoint": {"lat": 50.87033, "lon": 20.62752}}, {"facility": "Novartis Investigative Site", "city": "Bialystok", "zip": "15 276", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Novartis Investigative Site", "city": "Bialystok", "zip": "15-010", "country": "Poland", "geoPoint": {"lat": 53.13333, "lon": 23.16433}}, {"facility": "Novartis Investigative Site", "city": "Biaystok", "zip": "15-430", "country": "Poland"}, {"facility": "Novartis Investigative Site", "city": "Poznan", "zip": "60-214", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "Novartis Investigative Site", "city": "Poznan", "zip": "60-693", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "Novartis Investigative Site", "city": "Poznan", "zip": "60-823", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"facility": "Novartis Investigative Site", "city": "Strzelce Opolskie", "zip": "47 100", "country": "Poland", "geoPoint": {"lat": 50.5107, "lon": 18.30056}}, {"facility": "Novartis Investigative Site", "city": "Ploiesti", "state": "Prahova", "zip": "100024", "country": "Romania", "geoPoint": {"lat": 44.95, "lon": 26.01667}}, {"facility": "Novartis Investigative Site", "city": "Constanta", "state": "ROM", "zip": "900412", "country": "Romania", "geoPoint": {"lat": 44.18073, "lon": 28.63432}}, {"facility": "Novartis Investigative Site", "city": "Timisoara", "state": "Timis", "zip": "300310", "country": "Romania", "geoPoint": {"lat": 45.75372, "lon": 21.22571}}, {"facility": "Novartis Investigative Site", "city": "Arad", "zip": "310013", "country": "Romania", "geoPoint": {"lat": 46.18333, "lon": 21.31667}}, {"facility": "Novartis Investigative Site", "city": "Bragadiru", "zip": "077025", "country": "Romania", "geoPoint": {"lat": 44.37111, "lon": 25.9775}}, {"facility": "Novartis Investigative Site", "city": "Brasov", "zip": "500051", "country": "Romania", "geoPoint": {"lat": 45.64861, "lon": 25.60613}}, {"facility": "Novartis Investigative Site", "city": "Brasov", "zip": "500086", "country": "Romania", "geoPoint": {"lat": 45.64861, "lon": 25.60613}}, {"facility": "Novartis Investigative Site", "city": "Brasov", "zip": "500283", "country": "Romania", "geoPoint": {"lat": 45.64861, "lon": 25.60613}}, {"facility": "Novartis Investigative Site", "city": "Brasov", "zip": "500366", "country": "Romania", "geoPoint": {"lat": 45.64861, "lon": 25.60613}}, {"facility": "Novartis Investigative Site", "city": "Bucharest", "zip": "030317", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"facility": "Novartis Investigative Site", "city": "Bucuresti", "zip": "050554", "country": "Romania", "geoPoint": {"lat": 44.42802, "lon": 26.09665}}, {"facility": "Novartis Investigative Site", "city": "Cluj Napoca", "zip": "400139", "country": "Romania", "geoPoint": {"lat": 46.76667, "lon": 23.6}}, {"facility": "Novartis Investigative Site", "city": "Cluj Napoca", "zip": "400371", "country": "Romania", "geoPoint": {"lat": 46.76667, "lon": 23.6}}, {"facility": "Novartis Investigative Site", "city": "Deva", "zip": "330162", "country": "Romania", "geoPoint": {"lat": 45.88333, "lon": 22.9}}, {"facility": "Novartis Investigative Site", "city": "Oradea", "zip": "410176", "country": "Romania", "geoPoint": {"lat": 47.0458, "lon": 21.91833}}, {"facility": "Novartis Investigative Site", "city": "Sangiorgiu De Mures", "zip": "547530", "country": "Romania"}, {"facility": "Novartis Investigative Site", "city": "Singapore", "state": "SGP", "zip": "117599", "country": "Singapore", "geoPoint": {"lat": 1.28967, "lon": 103.85007}}, {"facility": "Novartis Investigative Site", "city": "Singapore", "zip": "169608", "country": "Singapore", "geoPoint": {"lat": 1.28967, "lon": 103.85007}}, {"facility": "Novartis Investigative Site", "city": "Singapore", "zip": "529889", "country": "Singapore", "geoPoint": {"lat": 1.28967, "lon": 103.85007}}, {"facility": "Novartis Investigative Site", "city": "Barcelona", "zip": "08006", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Novartis Investigative Site", "city": "Basel", "zip": "4031", "country": "Switzerland", "geoPoint": {"lat": 47.55839, "lon": 7.57327}}, {"facility": "Novartis Investigative Site", "city": "Liestal", "zip": "4410", "country": "Switzerland", "geoPoint": {"lat": 47.48455, "lon": 7.73446}}, {"facility": "Novartis Investigative Site", "city": "Lugano", "zip": "6900", "country": "Switzerland", "geoPoint": {"lat": 46.01008, "lon": 8.96004}}, {"facility": "Novartis Investigative Site", "city": "St Gallen", "zip": "9007", "country": "Switzerland", "geoPoint": {"lat": 47.42391, "lon": 9.37477}}, {"facility": "Novartis Investigative Site", "city": "Zurich", "zip": "8032", "country": "Switzerland", "geoPoint": {"lat": 47.36667, "lon": 8.54999}}, {"facility": "Novartis Investigative Site", "city": "Cambridge", "state": "Cambrigdeshire", "zip": "CB2 0QQ", "country": "United Kingdom", "geoPoint": {"lat": 52.2, "lon": 0.11667}}, {"facility": "Novartis Investigative Site", "city": "Darlington", "state": "Durham", "zip": "DL3 6HX", "country": "United Kingdom", "geoPoint": {"lat": 54.52429, "lon": -1.55039}}, {"facility": "Novartis Investigative Site", "city": "London", "state": "GBR", "zip": "EC1M 6BQ", "country": "United Kingdom", "geoPoint": {"lat": 51.50853, "lon": -0.12574}}, {"facility": "Novartis Investigative Site", "city": "Sheffield", "state": "South Yorkshire", "zip": "S10 2JF", "country": "United Kingdom", "geoPoint": {"lat": 53.38297, "lon": -1.4659}}, {"facility": "Novartis Investigative Site", "city": "Bradford", "state": "West Yorkshire", "zip": "BD9 6RJ", "country": "United Kingdom", "geoPoint": {"lat": 53.79391, "lon": -1.75206}}, {"facility": "Novartis Investigative Site", "city": "Birmingham", "zip": "B15 2WB", "country": "United Kingdom", "geoPoint": {"lat": 52.48142, "lon": -1.89983}}, {"facility": "Novartis Investigative Site", "city": "Birmingham", "zip": "B9 5SS", "country": "United Kingdom", "geoPoint": {"lat": 52.48142, "lon": -1.89983}}, {"facility": "Novartis Investigative Site", "city": "Cardiff", "zip": "CF14 4XW", "country": "United Kingdom", "geoPoint": {"lat": 51.48, "lon": -3.18}}, {"facility": "Novartis Investigative Site", "city": "Chertsey", "zip": "KT16 0PZ", "country": "United Kingdom", "geoPoint": {"lat": 51.38812, "lon": -0.50782}}, {"facility": "Novartis Investigative Site", "city": "East Yorkshire", "zip": "HU16 5JQ", "country": "United Kingdom"}, {"facility": "Novartis Investigative Site", "city": "Leicester", "zip": "LE3 9QP", "country": "United Kingdom", "geoPoint": {"lat": 52.6386, "lon": -1.13169}}, {"facility": "Novartis Investigative Site", "city": "Nottingham", "zip": "NG5 1PB", "country": "United Kingdom", "geoPoint": {"lat": 52.9536, "lon": -1.15047}}, {"facility": "Novartis Investigative Site", "city": "Plymouth", "zip": "PL6 8DH", "country": "United Kingdom", "geoPoint": {"lat": 50.37153, "lon": -4.14305}}, {"facility": "Novartis Investigative Site", "city": "Tyne And Wear", "zip": "NE29 8NH", "country": "United Kingdom"}, {"facility": "Novartis Investigative Site", "city": "Wakefield", "zip": "WF1 4DG", "country": "United Kingdom", "geoPoint": {"lat": 53.68331, "lon": -1.49768}}, {"facility": "Novartis Investigative Site", "city": "Wishaw", "zip": "ML2 0DP", "country": "United Kingdom", "geoPoint": {"lat": 55.76667, "lon": -3.91667}}, {"facility": "Novartis Investigative Site", "city": "Ho Chi Minh", "state": "VNM", "zip": "700000", "country": "Vietnam", "geoPoint": {"lat": 10.82302, "lon": 106.62965}}, {"facility": "Novartis Investigative Site", "city": "Hanoi", "zip": "100000", "country": "Vietnam", "geoPoint": {"lat": 21.0245, "lon": 105.84117}}, {"facility": "Novartis Investigative Site", "city": "Ho Chi Minh", "zip": "700000", "country": "Vietnam", "geoPoint": {"lat": 10.82302, "lon": 106.62965}}]}, "referencesModule": {"references": [{"pmid": "32979986", "type": "DERIVED", "citation": "Brightling CE, Gaga M, Inoue H, Li J, Maspero J, Wenzel S, Maitra S, Lawrence D, Brockhaus F, Lehmann T, Brindicci C, Knorr B, Bleecker ER. Effectiveness of fevipiprant in reducing exacerbations in patients with severe asthma (LUSTER-1 and LUSTER-2): two phase 3 randomised controlled trials. Lancet Respir Med. 2021 Jan;9(1):43-56. doi: 10.1016/S2213-2600(20)30412-4. Epub 2020 Sep 24."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The study included a Screening period of up to 2 weeks and a Placebo Run-in period of 2 to 6 weeks, during which eligibility for randomization was determined.", "recruitmentDetails": "Participants were from Argentina, Australia, Austria, Belgium, Brazil, China, Denmark, Estonia, Finland, France, Germany, Greece, Guatemala, Hungary, Latvia, Lithuania, Philippines, Poland, Romania, Singapore, Spain, Switzerland, UK, US, Vietnam.", "groups": [{"id": "FG000", "title": "QAW039 150 mg", "description": "QAW039 150 mg once daily"}, {"id": "FG001", "title": "QAW039 450 mg", "description": "QAW039 450 mg once daily"}, {"id": "FG002", "title": "Placebo", "description": "Placebo once daily"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "301"}, {"groupId": "FG001", "numSubjects": "295"}, {"groupId": "FG002", "numSubjects": "298"}]}, {"type": "FAS/SAF: High Eosinophil Subpopulation", "comment": "Full analysis set/safety set. All patients who received study drug and had high eosinophils count", "achievements": [{"groupId": "FG000", "numSubjects": "200"}, {"groupId": "FG001", "numSubjects": "201"}, {"groupId": "FG002", "numSubjects": "201"}]}, {"type": "FAS/SAF: Overall Population", "comment": "Full analysis set/safety set. All patients who received study drug", "achievements": [{"groupId": "FG000", "numSubjects": "299"}, {"groupId": "FG001", "numSubjects": "293"}, {"groupId": "FG002", "numSubjects": "298"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "282"}, {"groupId": "FG001", "numSubjects": "278"}, {"groupId": "FG002", "numSubjects": "269"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "19"}, {"groupId": "FG001", "numSubjects": "17"}, {"groupId": "FG002", "numSubjects": "29"}]}], "dropWithdraws": [{"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Technical Problems", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Protocol deviation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Subject/guardian decision", "reasons": [{"groupId": "FG000", "numSubjects": "12"}, {"groupId": "FG001", "numSubjects": "12"}, {"groupId": "FG002", "numSubjects": "22"}]}, {"type": "Death post Treatment/safety period", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "QAW039 150 mg", "description": "QAW039 150 mg once daily"}, {"id": "BG001", "title": "QAW039 450 mg", "description": "QAW039 450 mg once daily"}, {"id": "BG002", "title": "Placebo", "description": "Placebo once daily"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "301"}, {"groupId": "BG001", "value": "295"}, {"groupId": "BG002", "value": "298"}, {"groupId": "BG003", "value": "894"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "49.9", "spread": "14.97"}, {"groupId": "BG001", "value": "51.1", "spread": "14.29"}, {"groupId": "BG002", "value": "50.3", "spread": "14.48"}, {"groupId": "BG003", "value": "50.4", "spread": "14.58"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "192"}, {"groupId": "BG001", "value": "214"}, {"groupId": "BG002", "value": "177"}, {"groupId": "BG003", "value": "583"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "109"}, {"groupId": "BG001", "value": "81"}, {"groupId": "BG002", "value": "121"}, {"groupId": "BG003", "value": "311"}]}]}]}, {"title": "Race/Ethnicity, Customized", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Caucasian", "measurements": [{"groupId": "BG000", "value": "214"}, {"groupId": "BG001", "value": "215"}, {"groupId": "BG002", "value": "213"}, {"groupId": "BG003", "value": "642"}]}, {"title": "Black", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "6"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "29"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "45"}, {"groupId": "BG001", "value": "38"}, {"groupId": "BG002", "value": "44"}, {"groupId": "BG003", "value": "127"}]}, {"title": "Native American", "measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "24"}, {"groupId": "BG003", "value": "77"}]}, {"title": "Unknown", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}, {"groupId": "BG003", "value": "6"}]}, {"title": "Other", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "13"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation", "description": "A severe asthma exacerbation is defined as treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days and hospitalization; or treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days and emergency department visit (greater than 24 hours\\*); or death due to asthma. A moderate asthma exacerbation is defined as treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days either as an outpatient or in emergency department visits (Emergency department visit less than or equal to 24 hours). The high eosinophils subpopulation consists of all patients with blood eosinophil count \u2265 250 cells/\u03bcL at baseline.", "populationDescription": "Full Analysis Set (FAS) in high eosinophils subpopulation (count \u2265 250 cells/\u03bcL)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "events/year", "timeFrame": "Baseline, Week 52", "groups": [{"id": "OG000", "title": "QAW039 150 mg", "description": "QAW039 150 mg once daily"}, {"id": "OG001", "title": "QAW039 450 mg", "description": "QAW039 450 mg once daily"}, {"id": "OG002", "title": "Placebo", "description": "Placebo once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "200"}, {"groupId": "OG001", "value": "201"}, {"groupId": "OG002", "value": "201"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.97", "lowerLimit": "0.78", "upperLimit": "1.20"}, {"groupId": "OG001", "value": "0.77", "lowerLimit": "0.62", "upperLimit": "0.97"}, {"groupId": "OG002", "value": "0.93", "lowerLimit": "0.75", "upperLimit": "1.16"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.800", "pValueComment": "adjusted p-value", "statisticalMethod": "negative binomial regression model", "statisticalComment": "Adjusted p-values obtained from the closed testing procedure", "paramType": "rate ratio", "paramValue": "1.04", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.77", "ciUpperLimit": "1.41"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.510", "pValueComment": "adjusted p-value", "statisticalMethod": "negative binomial regression model", "statisticalComment": "Adjusted p-values are based on the closed testing procedure", "paramType": "Rate Ratio", "paramValue": "0.83", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.61", "ciUpperLimit": "1.14"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for Participants 12 Years and Older (AQLQ+12) Score in High Eosinophils Subpopulation", "description": "The AQLQ+12 is comprised of a total of 32 individual questions that span a total of four domains: symptoms, activity limitation, emotional function, and environmental stimuli.\n\nPatients were asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale (7 = not at all impaired to 1 = severely impaired). The AQLQ+12 yields individual domain scores, which is the mean of all items in each domain, and an overall score, which is the mean of all 32 individual responses. Higher scores indicate less impairment in health-related quality of life. The high eosinophils subpopulation consists of all patients with blood eosinophil count \u2265 250 cells/\u03bcL at baseline.", "populationDescription": "Full Analysis Set (FAS) in high eosinophils subpopulation (count \u2265 250 cells/\u03bcL)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on scale", "timeFrame": "52 weeks", "groups": [{"id": "OG000", "title": "QAW039 150 mg", "description": "QAW039 150 mg once daily"}, {"id": "OG001", "title": "QAW039 450 mg", "description": "QAW039 450 mg once daily"}, {"id": "OG002", "title": "Placebo", "description": "Placebo once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "200"}, {"groupId": "OG001", "value": "201"}, {"groupId": "OG002", "value": "201"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.75", "spread": "0.067"}, {"groupId": "OG001", "value": "0.81", "spread": "0.067"}, {"groupId": "OG002", "value": "0.68", "spread": "0.067"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.819", "pValueComment": "adjusted p-value", "statisticalMethod": "ANCOVA", "statisticalComment": "Adjusted p-values obtained from the closed testing procedure", "paramType": "Mean Difference (Net)", "paramValue": "0.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.11", "ciUpperLimit": "0.26", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.095"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.591", "pValueComment": "adjusted p-vale", "statisticalMethod": "ANCOVA", "statisticalComment": "Adjusted p-values obtained from the closed testing procedure", "paramType": "Mean Difference (Net)", "paramValue": "0.14", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.05", "ciUpperLimit": "0.32", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.095"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 52 in Asthma Control Questionnaire-5(ACQ-5) Score in High Eosinophils Subpopulation", "description": "The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma control of a participant. Patients were asked to recall how their asthma had been during the previous week and to respond to the symptom questions on a 7-point scale (0=no impairment, 6=maximum impairment). The questions are equally weighted and the ACQ-5 score is the mean of the 5 questions: therefore, between 0 (totally controlled) and 6 (severely uncontrolled). The high eosinophils subpopulation consists of all patients with blood eosinophil count \u2265 250 cells/\u03bcL at baseline.", "populationDescription": "Full Analysis Set (FAS) in high eosinophils subpopulation (count \u2265 250 cells/\u03bcL)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on scale", "timeFrame": "Baseline, Week 52", "groups": [{"id": "OG000", "title": "QAW039 150 mg", "description": "QAW039 150 mg once daily"}, {"id": "OG001", "title": "QAW039 450 mg", "description": "QAW039 450 mg once daily"}, {"id": "OG002", "title": "Placebo", "description": "Placebo once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "200"}, {"groupId": "OG001", "value": "201"}, {"groupId": "OG002", "value": "201"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.88", "spread": "0.069"}, {"groupId": "OG001", "value": "-0.94", "spread": "0.069"}, {"groupId": "OG002", "value": "-0.76", "spread": "0.070"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.819", "pValueComment": "adjusted p-value", "statisticalMethod": "ANCOVA", "statisticalComment": "Adjusted p-values obtained from the closed testing procedure", "paramType": "Mean Difference (Net)", "paramValue": "-0.12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.31", "ciUpperLimit": "0.07", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.098"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.591", "pValueComment": "adjusted p-value", "statisticalMethod": "ANCOVA", "statisticalComment": "Adjusted p-values obtained from the closed testing procedure", "paramType": "Mean Difference (Net)", "paramValue": "-0.17", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.37", "ciUpperLimit": "0.02", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.098"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 52 in Pre-dose Forced Expiratory Volume in 1 Second (FEV1) in High Eosinophils Subpopulation", "description": "Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Baseline is defined as the last available FEV1 measurement taken prior to the first dose of randomized study drug. The high eosinophils subpopulation consists of all patients with blood eosinophil count \u2265 250 cells/\u03bcL at baseline.", "populationDescription": "Full Analysis Set (FAS) in high eosinophils subpopulation (count \u2265 250 cells/\u03bcL)", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "Baseline, Week 52", "groups": [{"id": "OG000", "title": "QAW039 150 mg", "description": "QAW039 150 mg once daily"}, {"id": "OG001", "title": "QAW039 450 mg", "description": "QAW039 450 mg once daily"}, {"id": "OG002", "title": "Placebo", "description": "Placebo once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "200"}, {"groupId": "OG001", "value": "201"}, {"groupId": "OG002", "value": "201"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.169", "spread": "0.0257"}, {"groupId": "OG001", "value": "0.153", "spread": "0.0255"}, {"groupId": "OG002", "value": "0.103", "spread": "0.0260"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.800", "pValueComment": "adjusted p-value", "statisticalMethod": "ANCOVA", "statisticalComment": "Adjusted p-values obtained from the closed testing procedure", "paramType": "Mean Difference (Net)", "paramValue": "0.067", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.005", "ciUpperLimit": "0.139", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0365"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.523", "pValueComment": "adjusted p-value", "statisticalMethod": "ANCOVA", "statisticalComment": "Adjusted p-values obtained from the closed testing procedure", "paramType": "Mean Difference (Net)", "paramValue": "0.050", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.021", "ciUpperLimit": "0.121", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0363"}]}, {"type": "PRIMARY", "title": "Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in Overall Population", "description": "A severe asthma exacerbation is defined as treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days and hospitalization; or treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days and emergency department visit (greater than 24 hours\\*); or death due to asthma. A moderate asthma exacerbation is defined as treatment with 'rescue' systemic corticosteroids for greater than or equal to 3 days either as an outpatient or in emergency department visits (Emergency department visit less than or equal to 24 hours).", "populationDescription": "Full Analysis Set (FAS) in overall population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "events/year", "timeFrame": "Baseline, Week 52", "groups": [{"id": "OG000", "title": "QAW039 150 mg", "description": "QAW039 150 mg once daily"}, {"id": "OG001", "title": "QAW039 450 mg", "description": "QAW039 450 mg once daily"}, {"id": "OG002", "title": "Placebo", "description": "Placebo once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "299"}, {"groupId": "OG001", "value": "293"}, {"groupId": "OG002", "value": "298"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.92", "lowerLimit": "0.77", "upperLimit": "1.09"}, {"groupId": "OG001", "value": "0.75", "lowerLimit": "0.62", "upperLimit": "0.90"}, {"groupId": "OG002", "value": "0.96", "lowerLimit": "0.80", "upperLimit": "1.15"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.819", "pValueComment": "adjusted p-value", "statisticalMethod": "negative binomial regression model", "statisticalComment": "Adjusted p-values obtained from the closed testing procedure", "paramType": "rate ratio", "paramValue": "0.96", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.75", "ciUpperLimit": "1.22"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.510", "pValueComment": "adjusted p-value", "statisticalMethod": "negative binomial regression model", "statisticalComment": "Adjusted p-values are based on the closed testing procedure", "paramType": "Rate Ratio", "paramValue": "0.78", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.61", "ciUpperLimit": "1.01"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 52 in Asthma Quality of Life Questionnaire for Participants 12 Years and Older (AQLQ+12) Score in Overall Population", "description": "The AQLQ+12 is comprised of a total of 32 individual questions that span a total of four domains: symptoms, activity limitation, emotional function, and environmental stimuli.\n\nPatients were asked to recall their experiences during the previous 2 weeks and to score each item on a 7-point scale (7 = not at all impaired to 1 = severely impaired). The AQLQ+12 yields individual domain scores, which is the mean of all items in each domain, and an overall score, which is the mean of all 32 individual responses. Higher scores indicate less impairment in health-related quality of life.", "populationDescription": "Full Analysis Set (FAS) in overall population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on scale", "timeFrame": "Baseline, Week 52", "groups": [{"id": "OG000", "title": "QAW039 150 mg", "description": "QAW039 150 mg once daily"}, {"id": "OG001", "title": "QAW039 450 mg", "description": "QAW039 450 mg once daily"}, {"id": "OG002", "title": "Placebo", "description": "Placebo once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "299"}, {"groupId": "OG001", "value": "293"}, {"groupId": "OG002", "value": "298"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.68", "spread": "0.053"}, {"groupId": "OG001", "value": "0.73", "spread": "0.054"}, {"groupId": "OG002", "value": "0.61", "spread": "0.054"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.819", "pValueComment": "adjusted p-value", "statisticalMethod": "ANCOVA", "statisticalComment": "Adjusted p-values obtained from the closed testing procedure", "paramType": "Mean Difference (Net)", "paramValue": "0.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.07", "ciUpperLimit": "0.23", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.076"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.591", "pValueComment": "adjusted p-vale", "statisticalMethod": "ANCOVA", "statisticalComment": "Adjusted p-values obtained from the closed testing procedure", "paramType": "Mean Difference (Net)", "paramValue": "0.12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.03", "ciUpperLimit": "0.27", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.076"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 52 in Asthma Control Questionnaire-5(ACQ-5) Score in Overall Population", "description": "The ACQ-5 is a five-item, self-completed questionnaire, which is used as a measure of asthma control of a participant. Patients were asked to recall how their asthma had been during the previous week and to respond to the symptom questions on a 7-point scale (0=no impairment, 6=maximum impairment). The questions are equally weighted and the ACQ-5 score is the mean of the 5 questions: therefore, between 0 (totally controlled) and 6 (severely uncontrolled).", "populationDescription": "Full Analysis Set (FAS) overall population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "units on scale", "timeFrame": "Baseline, Week 52", "groups": [{"id": "OG000", "title": "QAW039 150 mg", "description": "QAW039 150 mg once daily"}, {"id": "OG001", "title": "QAW039 450 mg", "description": "QAW039 450 mg once daily"}, {"id": "OG002", "title": "Placebo", "description": "Placebo once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "299"}, {"groupId": "OG001", "value": "293"}, {"groupId": "OG002", "value": "298"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.83", "spread": "0.055"}, {"groupId": "OG001", "value": "-0.90", "spread": "0.056"}, {"groupId": "OG002", "value": "-0.71", "spread": "0.056"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.819", "pValueComment": "adjusted p-value", "statisticalMethod": "ANCOVA", "statisticalComment": "Adjusted p-values obtained from the closed testing procedure", "paramType": "Mean Difference (Net)", "paramValue": "-0.11", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.27", "ciUpperLimit": "0.04", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.079"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.591", "pValueComment": "adjusted p-value", "statisticalMethod": "ANCOVA", "statisticalComment": "Adjusted p-values obtained from the closed testing procedure", "paramType": "Mean Difference (Net)", "paramValue": "-0.19", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.35", "ciUpperLimit": "-0.04", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.079"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Week 52 in Pre-dose Forced Expiratory Volume in 1 Second (FEV1) in Overall Population", "description": "Forced Expiratory Volume in one second (FEV1) is calculated as the volume of air forcibly exhaled in one second as measured by a spirometer. Baseline is defined as the last available FEV1 measurement taken prior to the first dose of randomized study drug.", "populationDescription": "Full Analysis Set (FAS) in overall population", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "Liter", "timeFrame": "Baseline, Week 52", "groups": [{"id": "OG000", "title": "QAW039 150 mg", "description": "QAW039 150 mg once daily"}, {"id": "OG001", "title": "QAW039 450 mg", "description": "QAW039 450 mg once daily"}, {"id": "OG002", "title": "Placebo", "description": "Placebo once daily"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "299"}, {"groupId": "OG001", "value": "293"}, {"groupId": "OG002", "value": "298"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.144", "spread": "0.0205"}, {"groupId": "OG001", "value": "0.108", "spread": "0.0206"}, {"groupId": "OG002", "value": "0.068", "spread": "0.0209"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.819", "pValueComment": "adjusted p-value", "statisticalMethod": "ANCOVA", "statisticalComment": "Adjusted p-values obtained from the closed testing procedure", "paramType": "Mean Difference (Net)", "paramValue": "0.076", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.019", "ciUpperLimit": "0.134", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0292"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.591", "pValueComment": "adjusted p-value", "statisticalMethod": "ANCOVA", "statisticalComment": "Adjusted p-values obtained from the closed testing procedure", "paramType": "Mean Difference (Net)", "paramValue": "0.040", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.017", "ciUpperLimit": "0.097", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0292"}]}]}, "adverseEventsModule": {"frequencyThreshold": "4", "timeFrame": "Adverse events (AEs) are presented from first dose of study treatment until last dose of study treatment plus 7 days post treatment. Serious AEs (including the All-Cause Mortality data table) are presented from first dose of study treatment until last dose of study treatment plus 30 days post treatment, up to maximum duration of 56 weeks.", "description": "Any sign or symptom that occurs during the study treatment plus 7 days post treatment for adverse events and 30 days post treatment for serious adverse events.", "eventGroups": [{"id": "EG000", "title": "QAW039 150 mg", "description": "QAW039 150 mg", "deathsNumAffected": 0, "deathsNumAtRisk": 299, "seriousNumAffected": 33, "seriousNumAtRisk": 299, "otherNumAffected": 204, "otherNumAtRisk": 299}, {"id": "EG001", "title": "QAW039 450 mg", "description": "QAW039 450 mg", "deathsNumAffected": 1, "deathsNumAtRisk": 293, "seriousNumAffected": 30, "seriousNumAtRisk": 293, "otherNumAffected": 193, "otherNumAtRisk": 293}, {"id": "EG002", "title": "Placebo", "description": "Placebo", "deathsNumAffected": 2, "deathsNumAtRisk": 298, "seriousNumAffected": 32, "seriousNumAtRisk": 298, "otherNumAffected": 214, "otherNumAtRisk": 298}], "seriousEvents": [{"term": "Lymphadenopathy", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Acute coronary syndrome", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Atrial tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Cardio-respiratory arrest", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Coronary artery disease", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Myocardial ischaemia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Pericardial effusion", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Sinus tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Ventricular hypokinesia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Diaphragmatic hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Diverticulum intestinal", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Faecaloma", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Gastritis", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Hiatus hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Intestinal obstruction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Irritable bowel syndrome", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Large intestine polyp", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Megacolon", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Oesophageal food impaction", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Pancreatitis acute", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Umbilical hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Non-cardiac chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Pyrexia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Biliary colic", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Drug hypersensitivity", "organSystem": "Immune system disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Appendicitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Bacterial diarrhoea", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Chronic hepatitis C", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Cystitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Diverticulitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Herpes virus infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Influenza", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Pneumonia chlamydial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Rectal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Tracheobronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Upper respiratory tract infection bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Abdominal wound dehiscence", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Ankle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Femur fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Incisional hernia", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Radius fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Tendon rupture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Traumatic haematoma", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Ulna fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Wrist fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Electrocardiogram abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Hypoalbuminaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Type 2 diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Muscular weakness", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Spinal osteoarthritis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Tenosynovitis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Thoracic spinal stenosis", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Basal cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Epithelioid mesothelioma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Leiomyosarcoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Non-small cell lung cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Rectal cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Squamous cell carcinoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Testicular neoplasm", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Essential tremor", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Lumbar radiculopathy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Migraine", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Superior sagittal sinus thrombosis", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Completed suicide", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Acute kidney injury", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Glomerulonephritis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Glomerulonephritis chronic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Nephrolithiasis", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Renal colic", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Adnexa uteri cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Benign prostatic hyperplasia", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Ovarian cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 14, "numAtRisk": 298}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Nasal polyps", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Pulmonary embolism", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Pulmonary oedema", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}, {"term": "Aortic aneurysm", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 298}]}, {"term": "Hypertension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 298}]}], "otherEvents": [{"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 29, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 22, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 26, "numAtRisk": 298}]}, {"term": "Lower respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 12, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 298}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 43, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 37, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 49, "numAtRisk": 298}]}, {"term": "Rhinitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 12, "numAtRisk": 298}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 19, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 18, "numAtRisk": 298}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 35, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 35, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 31, "numAtRisk": 298}]}, {"term": "Upper respiratory tract infection bacterial", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 21, "numAtRisk": 298}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 18, "numAtRisk": 298}]}, {"term": "Viral upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 29, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 26, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 26, "numAtRisk": 298}]}, {"term": "Blood creatinine increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 13, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 9, "numAtRisk": 298}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 16, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 11, "numAtRisk": 298}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 28, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 22, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 24, "numAtRisk": 298}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 151, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 135, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 155, "numAtRisk": 298}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (22.1)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 11, "numAtRisk": 299}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 293}, {"groupId": "EG002", "numAffected": 13, "numAtRisk": 298}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "email": "Novartis.email@novartis.com", "phone": "862-778-8300"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2019-11-29", "uploadDate": "2020-05-04T05:52", "filename": "SAP_000.pdf", "size": 730120}, {"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2017-02-10", "uploadDate": "2020-05-04T05:52", "filename": "Prot_001.pdf", "size": 1352243}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Luxembourg"]}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M7591", "name": "Dyspnea", "relevance": "LOW"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000007210", "term": "Indoleacetic Acids"}], "ancestors": [{"id": "D000010937", "term": "Plant Growth Regulators"}, {"id": "D000006133", "term": "Growth Substances"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M10254", "name": "Indoleacetic Acids", "asFound": "Renal Dysfunction", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}